Open Access<p>Sarsasapogenin Suppresses RANKL-Induced Osteoclastogenesis in vitro and Prevents Lipopolysaccharide-Induced Bone Loss in vivo</p>
Author(s) -
Jiaxuan Peng,
Kai Zhao,
Jinjin Zhu,
Yanben Wang,
Peng Sun,
Qichang Yang,
Tan Zhang,
Weiqi Han,
Wenjun Hu,
Wanlei Yang,
Jing Ruan,
Yu Qian
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s256867
Subject(s) - osteoclast , rankl , bone resorption , osteolysis , in vivo , chemistry , cancer research , mapk/erk pathway , in vitro , pharmacology , medicine , microbiology and biotechnology , signal transduction , biochemistry , biology , activator (genetics) , receptor , dentistry
Osteoclasts are giant polynuclear cells; their main function is bone resorption. An increased number of osteoclasts and enhanced bone resorption exert significant effects on osteoclast-related bone-lytic diseases, including osteoporosis. Given the limitations of current therapies for osteolytic diseases, it is urgently required to develop safer and more effective alternatives. Sarsasapogenin, a major sapogenin from Anemarrhena asphodeloides Bunge, possesses potent antitumor effects and inhibits NF-κB and MAPK signaling. However, the manner in which it affects osteoclasts is unclear.